New 'Sandwich' strategy aims to boost leukemia survival without donor transplant
NCT ID NCT06507514
First seen Nov 21, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses the drug blinatumomab before and after an autologous (self-donated) stem cell transplant to try to clear remaining cancer cells and lower the chance of relapse. The main goals are to see if this combination is safe and improves survival. Only 4 participants will be enrolled in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.